ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2020

A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer.

M P Kolinsky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.